Posted inCardiology Internal Medicine news
Finerenone Provides Robust Protection Against Heart Failure Events Regardless of Baseline NYHA Functional Class
A prespecified analysis of the FINEARTS-HF trial confirms that finerenone reduces cardiovascular death and heart failure events in patients with HFmrEF and HFpEF across all symptomatic stages, offering the greatest absolute benefit to those with more severe functional limitations.